

GATTEX (teduglutide)

Effective Date: 4/22/14

Date Developed: 4/9/14 by Dr. Robert Sterling

Last Approval Date: 1/26/16, 1/24/17, 1/23/18

(Archived 1/22/19)

Gattex is a glucagon-like peptide manufactured by recombinant DNA technology which mimics the action of glucagon-like peptide-2 (GLP-2) which is secreted by the L-cells of the distal intestine. GLP-2 inhibits gastric acid secretion, increases portal blood flow and binds to enteroendocrine cells, resulting in the local release of multiple mediators (e.g. IGF-1, nitric oxide, etc)

Pre-Authorization Criteria: treatment of adult patients with Short Bowel Syndrome (SBS) who are dependent on parenteral nutritional support

Dosing: 0.05 mg.kg subcutaneously (*not* IM or IV); ½ dose if CCr<50 mL/min

How Supplied: 4 mg lyophilized powder in a single-use vial (reconstitute with 0.5 mL sterile water)

Contraindications/Warnings: avoid with active gastrointestinal malignancy or colorectal polyps; monitor for the development of acute biliary and pancreatic disease; fluid overload may occur due to enhanced fluid absorption

Major Adverse Reactions: **nausea** and abdominal distension; headache

Major Drug Interactions: possibility of increased absorption of oral medications

REFERENCES

Ferrone M and Scolapio JS, "Teduglutide for the Treatment of Short Bowel Syndrome," *Ann Pharmacother*, 2006, 40(6):1105-9.

Jeppesen PB, Gilroy R, Pertkiewicz M, et al, "Randomised Placebo-Controlled Trial of Teduglutide in Reducing Parenteral Nutrition and/or Intravenous Fluid Requirements in Patients With Short Bowel Syndrome," *Gut*, 2011, 60(7):902-14.

Jeppesen PB, Pertkiewicz M, Messing B, et al, "Teduglutide Reduces Need for Parenteral Support Among Patients With Short Bowel Syndrome With Intestinal Failure," *Gastroenterology*, 2012, 143(6):1473-81.

Revision History:

Date Approved by P&T Committee: 4/22/14
 Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
 Date Approved by P&T Committee: 1/27/15
 Date Reviewed/Updated: 3/31/15 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/26/16
 Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/24/17
 Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/23/18
 Date Reviewed/Archived: 1/22/19 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/22/19

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Archived – check MCG